Fig. 1

HE4-overexpressing cells are more resistant to cisplatin and paclitaxel treatment. SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with 0-12.5 μM cisplatin (a) or 0-5 nM paclitaxel (b) for 48 h, at which time the cells were subjected to MTS assay to measure viability. Results are displayed as percent survival of vehicle treated cells. Error bars represent the standard deviation of biological replicates. *p < .05, **p < .005, N/S = not significant (c) SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with vehicle (DMSO) or 5 μM cisplatin, and protein was collected at 24, 48, and 72 h after treatment. Western blot was performed to detect levels of PARP and cleaved PARP. d Densitometry analysis of PARP and cleaved PARP normalized to GAPDH, from western blot in (c). e SKOV3-NV, SKOV3-C1, and SKOV3-C7 cells were treated with 1 nM paclitaxel and protein was isolated from all cells (floating and adherent) 48 h after treatment. Western blot was performed to detect levels of PARP and cleaved PARP. GAPDH was used as a loading control. f Densitometry analysis of PARP and cleaved PARP normalized to GAPDH, from western blot in (e)